Cat#:RP-RANKL-02H;Product Name:Recombinant Human RANKL / OPGL / TNFSF11 / CD254 Protein (Fc Tag);Synonym:CD254,hRANKL2,ODF,OPGL,OPTB2,RANKL,sOdf,TRANCE;Description:A DNA sequence encoding the human RANKL/TNFSF11 (AAC51762.1) (Gly63-Asp244) was expressed with the Fc region of mouse IgG1 at the N-terminus. Recombinant human RANKL protein was produced in Human cells. The RANKL human recombinant protein was purified by our unique chromatographic techniques.;Source:Human Cells;Predicted N Terminal:Asp;Molecular Characterization:The recombinant human RANKL protein/Fc comprises 418 amino acids and has a predicted molecular mass of 47.1 kDa. The apparent molecular mass of the monomer is approximately 48-56 kDa in SDS-PAGE under reducing conditions due to glycosylation.;Purity:Greater than 90 % as determined by SDS-PAGE;Endotoxin:< 1.0 EU per μg of the recombinant human rankl protein as determined by the LAL method;Bioactivity:The bioactivity of recombinant human RANKL protein was determined by measuring the ability of human RANKL to induce TRAP activity in Raw 264.7 cells. The ED50 for this effect is typically 15-45 ng/mL.;Formulation:Recombinant human RANKL protein was lyophilized from sterile PBS, pH 7.4;Stability:Recombinant human RANKL Proteins are stable for up to 1 year from date of receipt at -70℃;Storage:Lyophilized recombinant human RANKL protein is stable at 4-8℃ for 2-4 weeks. Upon reconstitution, Recombinant human RANKL protein should be stored at 4°C between 2-7 days and for future use below -20°C. Avoid freeze-thaw cycles.;References:1. Leibbrandt A, et al. (2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50. 2.Schwarz EM, et al. (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther. 9 Suppl 1: S7.;